Association of Lipoprotein A, a Predisposing Risk Factor for In-stent Restenosis


  • Khurshid Ali PIC
  • Muhammad Amad Abbasi Punjab Institute of Cardiology, Lahore
  • Muhammad Aqeel Punjab Institute of Cardiology, Lahore
  • Habib ur Razaq Khyber Teaching Hospital, Peshawar
  • Khurram Shahzad Punjab Institute of Cardiology, Lahore



Lipoprotein A, in-stent restenosis, predisposing factor, Diabetes mellitus, Cardio-vascular disease.



Elevated plasma lipoprotein (A) concentration is considered as a predisposing risk factor for cardiovascular disease and in-stent restenosis. Lipoprotein (A) is a lipoprotein with an LDL-like particle that contains Apo-lipoprotein B100 and is associated with cardiovascular complications. The most prevalent complication associated with percutaneous coronary intervention is in-stent restenosis.In-stent Restenosis affected 40% of all angioplasties in the pre-stent era, then 28% in the (BMS) era. Furthermore, the introduction of (DES) second generation and drug-coated balloons has further reduced restenosis rates to less than 10%. The aim of this review paper is to investigate the clinical association of Lipoprotein (A) concentration in the occurrence of in-stent restenosis. Our paper possesses some limitations Firstly, it does not explain how lipoprotein concentrations are established. Secondly, the mechanism underlying the lipoprotein (A) lowering effect of current therapy.

Keywords: Lipoprotein A, in-stent restenosis, predisposing factor, Diabetes mellitus, Cardio-vascular disease.

Author Biographies

Khurshid Ali, PIC

Senior Registrar Cardiology

Muhammad Amad Abbasi, Punjab Institute of Cardiology, Lahore

Medical Officer

Muhammad Aqeel, Punjab Institute of Cardiology, Lahore

Senior Registrar Cardiology

Habib ur Razaq, Khyber Teaching Hospital, Peshawar

Medical Officer

Khurram Shahzad, Punjab Institute of Cardiology, Lahore

Assistant Professor of Cardiology


Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif J-C, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 2020;382(3):244–55.

Kamitani T, Taniguchi T, Miyai N, Kawasaki T. Association Between Plasma Lipoprotein ( a ) Concentration. 2005;644–9.

Park SH, Rha SW, Choi BG, Park JY, Jeon U, Seo HS, et al. Impact of high lipoprotein(a) levels on in-stent restenosis and long-term clinical outcomes of angina pectoris patients undergoing percutaneous coronary intervention with drug-eluting stents in Asian population. Clin Exp Pharmacol Physiol. 2015;42(6):588–95.

Rashidi B, Hoseini Z, Sahebkar A, Mirzaei H. Anti-Atherosclerotic Effects of Vitamins D and E in Suppression of Atherogenesis. J Cell Physiol. 2017;232(11):2968–76.

Wihanda D, Alwi I, Yamin M, Shatri H, Mudjaddid E. Factors Associated with In-stent Restenosis in Patients Following Percutaneous Coronary Intervention. Acta Med Indones. 2015;47(3):209–15.

Wang JL, Qin Z, Wang ZJ, Shi DM, Liu YY, Zhao YX, et al. New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent. J Geriatr Cardiol. 2018;15(2):137–45.

Lee MS, Banka G. In-stent Restenosis. Interv Cardiol Clin [Internet]. 2016;5(2):211–20. Available from:

Pleva L, Kukla P, Hlinomaz O. Treatment of coronary in-stent restenosis: A systematic review. J Geriatr Cardiol. 2018;15(2):173–84.

He WJ, Zhou Y, Liu JX, Liu J. Association of baseline high-density lipoprotein levels with restenosis after coronary stenting: A meta-analysis. Coron Artery Dis. 2013;24(5):386–91.

Qin S yu, Liu J, Jiang H xing, Hu B li, Zhou Y, Olkkonen VM. Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: Meta-analysis of 9 cohort studies. Atherosclerosis [Internet]. 2013;227(2):360–6. Available from:

Qin Z, Zhou K, Li YP, Wang JL, Cheng WJ, Hu CP, et al. Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: A single-centre observational cohort study. Cardiovasc Diabetol [Internet]. 2019;18(1):1–9. Available from:

Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: What have we learned and where are we going? the Andreas Grüntzig Lecture ESC 2014. Eur Heart J. 2015;36(47):3320–31.

Kim MS, Dean LS. In-Stent Restenosis. Cardiovasc Ther. 2011;29(3):190–8.

Waldmann E, Parhofer KG. Thematic review series: Lipoprotein (a): Coming of age at last Lipoprotein apheresis to treat elevated lipoprotein (a)1. J Lipid Res [Internet]. 2016;57(10):1751–7. Available from:

Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275–84.

Liu J, Liu Y, Jia K, Huo Z, Huo Q, Liu Z, et al. Clinical analysis of lectin-like oxidized low-density lipoprotein receptor-1 in patients with in-stent restenosis after percutaneous coronary intervention. Med (United States). 2018;97(17).

Kronenberg F. Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases. Cardiovasc Drugs Ther. 2016;30(1):87–100.

Zhao S, Xu J-J, Jiang L-Q, Chu Z-L, Tao A-Q, Jin L, et al. Occurrence and predictive risk factors associated with in-stent restenosis after drug-eluting stent implantation in diabetic patients: a prospective, clinical cohort study. 2020.

Jing XD, Wei XM, Deng SB, Du JL, Liu YJ, She Q. The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis. Clin Chim Acta [Internet]. 2015;446:248–52. Available from:

Malaguarnera M, Vacante M, Russo C, Malaguarnera G, Antic T, Malaguarnera L, et al. 650989. Drug Data Rep. 2009;31(3):308.

Shigematsu S, Takahashi N, Hara M, Yoshimatsu H, Saikawa T. Increased incidence of coronary in-stent restenosis in type 2 diabetic patients is related to elevated serum malondialdehyde-modified low-density lipoprotein. Circ J. 2007;71(11):1697–702.

Abhyankar A, Sandhu MS, Polavarapu RS. Twelve-month comparative analysis of clinical outcomes using biodegradable polymer–coated everolimus-eluting stents versus durable polymer–coated everolimus-eluting stents in all-comer patients. Indian Heart J [Internet]. 2019;71(2):149–54. Available from:

Qin Z, Zheng FW, Zeng C, Zhou K, Geng Y, Wang JL, et al. Elevated levels of very low-density lipoprotein cholesterol independently associated with in-stent restenosis in diabetic patients after drug-eluting stent implantation. Chin Med J (Engl). 2017;130(19):2326–32.

Florentin M, Elisaf MS, Rizos C V., Nikolaou V, Bilianou E, Pitsavos C, et al. l-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study. Lipids. 2017;52(1).

Palareti G, Legnani C, Cosmi B, Antonucci E, Erba N, Poli D, et al. Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study. Vol. 38, International Journal of Laboratory Hematology. 2016. 42–49 p.

Wang X, Love PED, Kim MJ, Park CS, Sing CP, Hou L. A conceptual framework for integrating building information modeling with augmented reality. Autom Constr [Internet]. 2013;34:37–44. Available from:





Review Article